The GH–IGF-I axis and breast cancer

Laban, C; Bustin, Stephen A.; Jenkins, Paul J.

doi:10.1016/s1043-2760(02)00003-6

Cited by 109 publications

(88 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings of several studies have suggested a possible relationship between the GH -IGF-I axis, PRL and mammary tumor formation (for reviews see 16,17,40,41). Patients with breast cancer exhibit increased serum concentrations of GH (42) and IGF-I (43), and autocrine production of human GH increases cell numbers in mammary carcinoma as a consequence of both increased mitogenesis and decreased apoptosis (44,45).…”

Section: Discussionmentioning

confidence: 99%

“…One study did not reveal Pit-1 mRNA in normal canine mammary tissues despite the presence of GH gene transcripts, but GH-expressing canine mammary tumors showed Pit-1 expression, suggesting a role for Pit-1 in mammary expression of GH after malignant transformation (15). In relation to this possibility, a relationship has been suggested between PRL, GH, insulin-like growth factor (IGF)-I and breast cancer (for reviews see 16,17). GH and PRL, together with the corresponding mRNAs and receptors, have been found in both normal human breast and mammary tumors (18 -22).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation

Gil¹,

Seoane²,

Blanco³

et al. 2005

eur j endocrinol

View full text Add to dashboard Cite

Background: The transcription factor pituitary-1 (Pit-1) is mainly expressed in the pituitary gland, where it has critical roles in cell differentiation and as a transcriptional factor for GH and prolactin (PRL). It is also expressed in human extrapituitary tissues (placenta, lymphoid and haematopoietic tissues) and cell lines (human breast adenocarcinoma cells, MCF-7). Despite the widely suggested roles of GH and PRL in the progression of proliferative mammary disorders, Pit-1 expression in human mammary gland has not yet been reported. Objective: To evaluate the expression of Pit-1 in human breast and, using the MCF-7 cell line, to investigate whether Pit-1 overexpression regulates GH expression and increases cell proliferation. Methods: Using real-time RT-PCR, western blotting and immunohistochemistry, we evaluated the expression of Pit-1 mRNA and protein in seven normal human breasts and 14 invasive ductal mammary carcinomas. GH regulation by Pit-1 in MCF-7 cells was evaluated using RT-PCR, western blotting, ELISA and transfection assays. Cell proliferation was evaluated using bromodeoxyuridine. Results: We found expression of Pit-1 mRNA and protein in both normal and tumorous human breast. We also found that Pit-1 mRNA levels were significantly increased in breast carcinoma compared with normal breast. In MCF-7 cells, Pit-1 overexpression increased GH mRNA and protein concentrations and significantly increased cell proliferation. Conclusions: These findings indicate that Pit-1 is expressed in human breast, that it regulates endogenous human mammary GH secretion, and that it increases cell proliferation. This suggests that, depending on its level of expression, Pit-1 may be involved in normal mammary development, breast disorders, or both.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation

Gil¹,

Seoane²,

Blanco³

et al. 2005

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…GH interacts with the stroma and with the epithelial tissue, leading to ductal elongation and differentiation of ductal epithelium into highly proliferative terminal end buds (TEBS) (Kleinberg, 1997;Walden et al, 1998). GH-infusions lead to a fourfold augmentation of mammary glandular size in primates, although it is unknown if this results are induced by GH or IGF-1 (Ng et al, 1997;Laban et al, 2003). In 1952 a regression of metastatic mammary tumours was reported after hypophysectomy (Luft et al, 1952;Perry et al, 2008) which led to hypophysectomy as therapy for breast cancer in the 1950´s (Ray et al, 1962;Waters & Barkley, 2007).…”

Section: Gh and Breast Cancermentioning

confidence: 99%

Growth hormone (GH) modulation of Epidermal growth factor (EGF) signalling in human mammary epithelial cells

Wölker¹

2015

JOSHA

View full text Add to dashboard Cite

show abstract

“…Diversos estudos epidemiológicos relataram a elevação dos níveis séricos de IGF-1 associada com o aumento do risco de câncer de mama e próstata e do câncer colorretal em humanos (42)(43)(44)(45). Além disso, a prolactina, hormônio hipofisá-rio relacionado com o GH, tem sido implicada no desenvolvimento de glândula mamária e na etiologia, tanto do carcinoma mamário quanto do câncer de prós-tata (46,47).…”

Section: Hormônio De Crescimento E Síndrome De Turnerunclassified

“…Sabe-se que o aumento de hGH circulante aumenta a expressão de IGF-1 que, por sua vez, tem sido implicado na gêne-se de diversos tipos de cânceres (42)(43)(44)(45). Existem grandes evidências de que o hGH, pelo aumento da expressão de IGF-1, provê maior ligação entre esses fatores e o desenvolvimento de câncer por meio da sua influência na regulação da proliferação, da diferenciação e da apoptose celular.…”

Section: Hormônio De Crescimento E Síndrome De Turnerunclassified

O hormônio de crescimento na síndrome de Turner: dados e reflexões

Guedes

Bianco

Callou

et al. 2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

A baixa estatura é a principal característica na síndrome de Turner (ST). O agravo estatural na ST é precoce e torna-se mais evidente na puberdade. A haploinsuficiência do gene SHOX tem sido implicada como principal fator na definição da estatura de mulheres, no entanto, ainda que a maioria das pacientes não tenha deficiência do hormônio de crescimento, a terapia com GHr melhora a altura final. Recentemente, tem-se chamado a atenção para a associação entre GH e câncer. O risco de câncer nessas pacientes está associado à presença de fragmentos do cromossomo Y que pode levar ao desenvolvimento de gonadoblastoma. Dessa forma, a administração de GHr na ST deve ser feita com cautela. A investigação de seqüências do cromossomo Y deve ser realizada, bem como a gonadectomia profilática nos casos positivos, conferindo maior segurança ao tratamento.

show abstract

The GH–IGF-I axis and breast cancer

Cited by 109 publications

References 115 publications

Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation

Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation

Growth hormone (GH) modulation of Epidermal growth factor (EGF) signalling in human mammary epithelial cells

O hormônio de crescimento na síndrome de Turner: dados e reflexões

Contact Info

Product

Resources

About